Phio Pharmaceuticals Corp. (PHIO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Phio Pharmaceuticals Corp. (PHIO) closed at USD 0.93 on 2026-10-15, a change of -55.2 % over the past year, with a market capitalization of USD 10.12M.

Phio Pharmaceuticals Corp. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Phio Pharmaceuticals Corp. key figures

Previous close

USD 0.93 (2026-10-15)

1-year change

-55.2 %

Market cap

USD 10.12M

Enterprise value

USD -2.88M

P/E ratio (trailing)

-0.68

P/E ratio (forward)

-1.43

EPS (trailing)

-1.29

EPS (forward)

-0.61

PEG ratio

n/a

Price to book

0.80

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.64

Employees

6

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Phio Pharmaceuticals Corp. and compare it with other stocks.